Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

PURPOSE: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC). PATIENTS AND METHOD...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Motzer, Robert J., Nosov, Dmitry, Eisen, Timothy, Bondarenko, Igor, Lesovoy, Vladimir, Lipatov, Oleg, Tomczak, Piotr, Lyulko, Oleksiy, Alyasova, Anna, Harza, Mihai, Kogan, Mikhail, Alekseev, Boris Y., Sternberg, Cora N., Szczylik, Cezary, Cella, David, Ivanescu, Cristina, Krivoshik, Andrew, Strahs, Andrew, Esteves, Brooke, Berkenblit, Anna, Hutson, Thomas E.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2013
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569677/
https://ncbi.nlm.nih.gov/pubmed/24019545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.4940
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars